Resources

Our community of economists and academic leaders from around the United States are united in their belief that more competition, innovation, accountability, consumer choice, and transparency are needed in America’s healthcare sector to improve the health and well-being of every patient.

Formulary-Related Insurance Denials of Single-Source Branded Drugs in the United States

July 15, 2026

JAMA

By Joseph F. Levy, PhD, G. Caleb Alexander, MD, Boris Vabson, PhD

Enhancing Prescription Drug Affordability Through Competition

June 17, 2026

JAMA Health Forum

By Brian Miller, MD, MBA, MPH, Lanhee J. Chen, JD, PhD

Stretching Scarce Authorizing Legislation as Far as Possible: A Legislative History of the 340B Drug Pricing Program

May 20, 2026

The Milbank Quarterly

By Sayeh Nikpay, Maikayla Reinke, Nicole Quinones

China is Winning the First Mile of Drug Innovation

May 11, 2026

Washington Examiner

By Stephen T. Parente

Op-ed at The Well News: The 340B Windfall That Misses Patients

May 4, 2026

The Well News

By Stephen T. Parente
Scroll to Top